KURAKura Oncology, Inc.
$9.61+3.5% 1Y
$9.61
$7.4052 weeks$13.59
Latest close: below its 200-day averageOct 23, 2026what changed →
The financials
Kura Oncology, Inc. by the numbers
Kura Oncology, Inc. (KURA) reported revenue of $21M in Q2 2026 (quarter ended Jun 30, 2026), up 37% from the same quarter a year earlier. That came with a gross margin of 99% and net loss of $68M. For the full year FY2025, revenue was $67M (+25% year on year) and net income −$279M. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $21M | $15M | +37% |
| Gross profit | $21M | n/a | n/a |
| Operating income | −$73M | −$73M | n/a |
| Net income | −$68M | −$66M | n/a |
| Diluted EPS | −$0.77 | −$0.75 | n/a |
Biotechnology
Ranks #101 of 194 by RyuScore